Rheumatology (Oxford)
-
Publication Venue For
- Longitudinal association of infrapatellar fat pad signal intensity alteration with biochemical biomarkers in knee osteoarthritis.. 62:439-449. 2022
- Improving outcomes in scleroderma: recent progress of cell-based therapies. 2022
- Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy.. 61:4155-4162. 2022
- Metabolomics analysis identifies a lipidomic profile in treatment-naïve juvenile dermatomyositis patients vs healthy control subjects.. 61:1699-1708. 2022
- Extracutaneous involvement is common and associated with prolonged disease activity and greater impact in juvenile localized scleroderma.. 60:5724-5733. 2021
- Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma.. 60:3817-3825. 2021
- ADA2 deficiency (DADA2) associated with Evans syndrome and a severe ADA2 genotype.. 60:e237-e239. 2021
- Conducting research in psoriatic arthritis: the emerging role of patient research partners.. 59:i47-i55. 2020
- Deficiency of adenosine deaminase 2: a case series revealing clinical manifestations, genotypes and treatment outcomes from Turkey.. 59:254-256. 2020
- Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.. 58:vii59-vii67. 2019
- Treatment failure in inflammatory arthritis: time to think about syndemics?. 58:1526-1533. 2019
- The SLE-key test serological signature: new insights into the course of lupus.. 57:1632-1640. 2018
- Power in numbers.. 57:v40-v47. 2018
- The new FDA labeling rule: impact on prescribing rheumatological medications during pregnancy.. 57:v2-v8. 2018
- Challenges and controversies of complex interventions in osteoarthritis management: recognizing inappropriate and discordant care.. 57:iv88-iv98. 2018
- The impact of menopause on functional status in women with rheumatoid arthritis.. 57:798-802. 2018
- Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample.. 57:694-702. 2018
- 2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects.. 56:1884-1893. 2017
- Transcriptional profiles of JIA patient blood with subsequent poor response to methotrexate.. 56:1542-1551. 2017
- Biosimilars in rheumatology: understanding the rigor of their development.. 56:187-197. 2017
- Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab.. 56:247-254. 2017
- Cartilage biomarkers in the osteoarthropathy of alkaptonuria reveal low turnover and accelerated ageing.. 56:156-164. 2017
- Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.. 55:1710. 2016
- Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.. 55:991-999. 2016
- Novel compound heterozygous variants in CECR1 gene associated with childhood onset polyarteritis nodosa and deficiency of ADA2.. 55:1145-1147. 2016
- Suppression of inflammatory disease activity in rheumatoid arthritis is associated with improvements in retinal microvascular health.. 55:246-251. 2016
- Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study.. 53:1613-1617. 2014
- Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.. 51:2204-2214. 2012
- Microparticles as mediators and biomarkers of rheumatic disease.. 51:1737-1746. 2012
- Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial.. 51:1628-1638. 2012
- Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.. 51:1226-1234. 2012
- Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis.. 50:1732-1736. 2011
- Retinal vascular calibre is altered in patients with rheumatoid arthritis: a biomarker of disease activity and cardiovascular risk?. 50:939-943. 2011
- A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.. 48:1114-1121. 2009
- Health-related quality of life in children and adolescents with juvenile localized scleroderma.. 48:670-672. 2009
- A large kindred of early-onset osteoarthritis of the knee and hip: excluding the link to COL2A1 gene.. 48:371-374. 2009
- The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices. 2018